A federal judge yesterday denied drug maker Novartis’ request to speed up a hearing on its request that the judge block the government from punishing the company over its denials of 340B pricing when health care providers use contract pharmacies.
…
Tom Mirga
U.S. Sen. Mike Braun (R-Ind.) introduced legislation last night to let the federal government audit 340B covered entities to determine how they use net income from drugs bought under the 340B program.
Please Login or Become
The U.S. Health Resources and Services Administration (HRSA) says it plans to resume some onsite 340B compliance audits of covered entities starting in October.
Please Login or Become a Paid Subscriber to View this Content
U.S. House GOP Conference Chair Elise Stefanik (N.Y.), the third highest-ranking House Republican, has issued a news release and tweeted about signing on as a sponsor of bipartisan legislation prohibiting pharmacy benefit managers (PBMs) and other third-party payers from paying
…
The federal government has started reviewing applications from individuals seeking to be the next Director of the U.S. Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA), the unit within HRSA that oversees the 340B program. Tuesday, Sept.
…
President Biden announced last week that he plans to nominate public health expert Robert Otto Valdez to serve as U.S. Health and Human Services (HHS) Assistant Secretary for Planning and Evaluation (ASPE).
Please Login or Become
U.S. House Energy & Commerce Republicans yesterday filed, but majority Democrats did not consider, four 340B-related amendments to budget legislation integral to enacting congressional Democrats and the Biden administration’s Build Back Better plan.
Please Login or
Former U.S. Health and Human Services Department General Counsel Robert Charrow yesterday defended his strongly worded and colorful December 2020 advisory opinion, since vacated by a court and withdrawn by HHS, that the 340B statute unambiguously requires drug manufacturers to
…
Champions for safety-net health care providers on one side and drug manufacturers and oncologists in private practice on the other faced off yesterday during a health care news service’s webinar on the 340B program.
Please Login
Hospitals in the 340B program and oncologists working in private practice have issued dueling reports about who profits unjustly in connection with the drug discount program.